Drug firm on Thursday said it has received approval from the US health regulator for Desipramine Hydrochloride tablets used in the treatment of depression.
The approved product is therapeutically equivalent to the reference listed drug product Norpramin tablets of Validus Pharmaceuticals LLC.
The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Desipramine Hydrochloride tablets USP in the strength of 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg, Pharmaceuticals said in a regulatory filing.
Desipramine Hydrochloride Tablets are indicated for the treatment of depression.
Quoting IQVIA data, Alembic Pharma said Desipramine Hydrochloride Tablets have an estimated market size of USD 7 million for twelve months ending March 2021.
Alembic has a cumulative total of 147 ANDA approvals (129 final approvals and 18 tentative approvals) from the USFDA.
The approved product is therapeutically equivalent to the reference listed drug product Norpramin tablets of Validus Pharmaceuticals LLC.
The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Desipramine Hydrochloride tablets USP in the strength of 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg, Pharmaceuticals said in a regulatory filing.
Desipramine Hydrochloride Tablets are indicated for the treatment of depression.
Quoting IQVIA data, Alembic Pharma said Desipramine Hydrochloride Tablets have an estimated market size of USD 7 million for twelve months ending March 2021.
Alembic has a cumulative total of 147 ANDA approvals (129 final approvals and 18 tentative approvals) from the USFDA.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.